Universal Biosensors, Inc. (ASX:UBI)

Market Cap	6.56M
Revenue (ttm)	6.37M
Net Income (ttm)	-14.64M
Shares Out	298.07M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,115,085
Average Volume	313,203
Open	0.0250
Previous Close	0.0240
Day's Range	0.0220 - 0.0250
52-Week Range	0.0170 - 0.1600
Beta	0.86
RSI	37.39
Earnings Date	Aug 8, 2025

About Universal Biosensors

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO₂, malic acid, glucose, fructose, total acid, and titratable acid...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 76
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: UBI

Financial Performance

In 2024, Universal Biosensors's revenue was 6.28 million, a decrease of -5.28% compared to the previous year's 6.63 million. Losses were -14.24 million, 111.2% more than in 2023.